Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 134 of 6351
-
Could a Pen-Sized shot stop a heart attack in its tracks?
Disease control By invitation onlyThis study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
Disease control Recruiting nowThe objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endosco…
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo aims to boost immune attack on tough melanoma
Disease control OngoingThis is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive brain metastasis or adolescents wi…
Phase 3 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy aims to cut deaths in HIV patients with widespread TB
Disease control OngoingThe New Strat-TB trial is a superiority Phase III randomised control clinical trial with a 2X2 factorial design. The main aim of the study is to assess the efficacy and safety of high dose rifampicin and levofloxacin for 14 days in addition to standard TB therapy with or without …
Phase 3 • Sponsor: University of Cape Town • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a lower dose of a Clot-Buster be safer and still effective for dangerous blood clots in the lungs?
Disease control OngoingIn this study, we will assess the efficacy and safety of a reduced dose of thrombolytic therapy given in addition to low-molecular-weight heparin in patients with intermediate-high-risk acute pulmonary embolism. Half of participants will receive thrombolytic treatment, while the …
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising new combo offers hope for rare, aggressive ovarian cancer
Disease control Recruiting nowSmall cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefitin…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a common blood pressure pill protect the aging brain?
Disease control CompletedIt has been recently discovered that the FDA-approved drug, hydralazine, has anti-neurodegenerative efficacy based on three intriguing observations. hydralazine; 1) activates the Nrf2 pathway that controls more than 200 antioxidant proteins, 2) rejuvenates mitochondria and increa…
Phase 3 • Sponsor: Shahid Sadoughi University of Medical Sciences and Health Services • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Brain pacemaker shows promise for severe OCD
Disease control CompletedThe present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that c…
Sponsor: Shanghai Mental Health Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
Disease control Stopped earlyCervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries. Cisplatin-based chemotherapy +/- bevacizumab have been recommended as the first-line treatment for patients who present with metastatic (e.g. …
Phase 2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Experimental drug aims to reverse liver scarring in NASH cirrhosis
Disease control CompletedThis is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
Phase 2 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: targeted drug combo faces off against standard care
Disease control OngoingThis study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to fight cervical cancer without chemo
Disease control OngoingThis study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enr…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
New combo therapy aims to wipe out rectal cancer before surgery
Disease control OngoingThe study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-term radiotherapy, sequential Camrelizumab and…
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThe purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage s…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
Disease control CompletedThis is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
Phase 3 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Brain artery stent coated with drug may cut stroke risk better than pills alone
Disease control Recruiting nowThe aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disea…
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
Disease control Recruiting nowThis research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatment…
Phase 2 • Sponsor: Jonathan Schoenfeld, MD, MPH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Groundbreaking trial aims to treat rare diseases in the womb
Disease control Recruiting nowFor detailed information, please view our study website: https://pearltrial.ucsf.edu/ The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
Phase 1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New vaccine aims to stop dangerous e. coli infections in seniors
Prevention CompletedThe purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serot…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingJ3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC